1. Apabetalone (RVX-208) Lowers Risk of Major Adverse Cardiovascular Events (MACE) in T2D Patients with CVD By Attenuating Monocyte Adhesion to Endothelial Cells. (June 2018) Authors: Tsujikawa, Laura; Kulikowski, Ewelina; Calosing, Cyrus; Wasiak, Sylwia; Gilham, Dean; Halliday, Christopher; Johansson, Jan; Sweeney, Mike; Wong, Norm Journal: Atherosclerosis Issue: Volume 32(2018) Page Start: 104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Apabetalone (RVX-208) may lower CVD events in diabetes mellitus by affecting complement pathway and microbiome activity. (August 2017) Authors: Kulikowski, Ewelina; Calosing, Cyrus; Tsujikawa, Laura; Wasiak, Sylwia; Gilham, Dean; Halliday, Christopher; Johansson, Jan; Sweeney, Michael; Wong, Norman Journal: Atherosclerosis Issue: Volume 263(2017) Page Start: e113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Apabetalone downregulates factors and pathways associated with vascular calcification. (January 2019) Authors: Gilham, Dean; Tsujikawa, Laura M.; Sarsons, Christopher D.; Halliday, Christopher; Wasiak, Sylwia; Stotz, Stephanie C.; Jahagirdar, Ravi; Sweeney, Michael; Johansson, Jan O.; Wong, Norman C.W.; Kalantar-Zadeh, Kamyar; Kulikowski, Ewelina Journal: Atherosclerosis Issue: Volume 280(2019) Page Start: 75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. BET inhibitor apabetalone (RVX-208) downregulates the complement cascade in primary human hepatocytes, in mice and in cardiovascular disease human patients. (September 2017) Authors: Wasiak, Sylwia; Gilham, Dean; Tsujikawa, Laura M.; Halliday, Christopher; Calosing, Cyrus; Jahagirdar, Ravi; Johansson, Jan; Sweeney, Michael; Wong, Norman C.; Kulikowski, Ewelina Journal: Molecular immunology Issue: Volume 89(2017:Sep.) Page Start: 127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48–57]. (October 2016) Authors: Gilham, Dean; Wasiak, Sylwia; Tsujikawa, Laura M.; Halliday, Christopher; Norek, Karen; Patel, Reena G.; Kulikowski, Ewelina; Johansson, Jan; Sweeney, Michael; Wong, Norman C.W. Journal: Atherosclerosis Issue: Volume 253(2016) Page Start: 345 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48–57]. (October 2016) Authors: Gilham, Dean; Wasiak, Sylwia; Tsujikawa, Laura M.; Halliday, Christopher; Norek, Karen; Patel, Reena G.; Kulikowski, Ewelina; Johansson, Jan; Sweeney, Michael; Wong, Norman C.W. Journal: Atherosclerosis Issue: Volume 253(2016) Page Start: 345 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells. (January 2023) Authors: Wasiak, Sylwia; Tsujikawa, Laura M.; Daze, Emily; Gilham, Dean; Stotz, Stephanie C.; Rakai, Brooke D.; Sarsons, Chris D.; Fu, Li; Azhar, Salman; Jahagirdar, Ravi; Sweeney, Michael; Johansson, Jan O.; Wong, Norman C.W.; Kulikowski, Ewelina Journal: Atherosclerosis Issue: Volume 364(2023) Page Start: 10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease. (1st August 2020) Authors: Wasiak, Sylwia; Gilham, Dean; Daze, Emily; Tsujikawa, Laura M.; Halliday, Christopher; Stotz, Stephanie C.; Rakai, Brooke D.; Fu, Li; Jahagirdar, Ravi; Sweeney, Michael; Johansson, Jan O.; Wong, Norman C. W.; Kulikowski, Ewelina Other Names: De Luca Leonardo Academic Editor. Journal: Cardiovascular therapeutics Issue: Volume 2020(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. FP294INHIBITION OF BET PROTEINS WITH APABETALONE REDUCES MEDIATORS OF VASCULAR CALCIFICATION IN VITRO AND IN CKD PATIENTS. (18th May 2018) Authors: Gilham, Dean; Tsujikawa, Laura; Wasiak, Sylwia; Halliday, Chris; Sarsons, Chris; Stotz, Stephanie; Kalantar-Zadeh, Kam; Jahagirdar, Ravi; Johansson, Jan; Wong, Norman; Sweeney, Mike; Robson, Richard; Kulikowski, Ewelina Journal: Nephrology dialysis transplantation Issue: Volume 33(2018)Supplement 1 Page Start: i130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. MO072APABETALONE DOWNREGULATES FIBROTIC, INFLAMMATORY AND CALCIFIC PROCESSES IN RENAL MESANGIAL CELLS WHICH MAY CONTRIBUTE TO REDUCED CARDIAC EVENTS OBSERVED IN CKD PATIENTS. (29th May 2021) Authors: Gilham, Dean; Fu, Li; Rakai, Brooke; Wasiak, Sylwia; Tsujikawa, Laura; Halliday, Christopher; Sarsons, Christopher; Stotz, Stephanie; Jahagirdar, Ravi; Johansson, Jan; Sweeney, Michael; Wong, Norman; Kalantar-Zadeh, Kamyar; Kulikowski, Ewelina Journal: Nephrology dialysis transplantation Issue: Volume 36(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗